Cytomx Therapeutics Stock Investor Sentiment

CTMX Stock  USD 0.74  0.04  4.60%   
Slightly above 67% of CytomX Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding CytomX Therapeutics suggests that many traders are alarmed. CytomX Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CytomX Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

CytomX Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards CytomX Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
55.3%
54.5%
59.1%
51.5%
53.3%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
CytomX Therapeutics to Release Quarterly Earnings on Monday - Defense World
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
CytomX Therapeutics to Release Quarterly Earnings on Monday
news
over six months ago at simplywall.st         
CytomX Therapeutics, Inc.s Price Is Right But Growth Is Lacking After Shares Rocket 85
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Yahoo News
over six months ago at investing.com         
CytomX Therapeutics Inc earnings missed by 0.03, revenue fell short of estimates
Investing News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Timothy Shannon of 14000 shares of CytomX Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at zacks.com         
CytomX to Report Q4 Earnings Heres What to Expect
zacks News
over six months ago at simplywall.st         
Even after rising 12 percent this past week, CytomX Therapeutics shareholders are still down 85 perc...
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Short Interest in CytomX Therapeutics, Inc. Decreases By 5.3 percent - MarketBeat
Google News at Macroaxis
over a year ago at finance.yahoo.com         
CytomX Therapeutics, Inc.s largest shareholders are retail investors with 50 percent ownership, inst...
Yahoo News
over a year ago at news.google.com         
Q1 2021 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus.com
Google News at Macroaxis
over a year ago at news.google.com         
CytomX Therapeutics Stock Crosses Above 50-Day Moving Average of 1.52 - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
MRK Will These 3 Pharma Stocks Leave Investors Triumphant in 2024 - StockNews.com
Google News at Macroaxis
over a year ago at zacks.com         
Apellis Down on Negative CHMP Opinion for Pegcetacoplan
zacks News
over a year ago at zacks.com         
SpringWorks Surges More Than 80 percent in 3 Months Heres Why
zacks News
Far too much social signal, news, headlines, and media speculation about CytomX Therapeutics that are available to investors today. That information is available publicly through CytomX media outlets and privately through word of mouth or via CytomX internal channels. However, regardless of the origin, that massive amount of CytomX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytomX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytomX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytomX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytomX Therapeutics alpha.

CytomX Therapeutics Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.151234567891011Dec2025Feb -20-1001020
JavaScript chart by amCharts 3.21.15CytomX Therapeutics CytomX Therapeutics Dividend Benchmark Dow Jones Industrial
       Timeline  
1
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
12/16/2024
2
Disposition of 11250 shares by Rowland Lloyd A of CytomX Therapeutics subject to Rule 16b-3
12/27/2024
3
Peninsula biotech to lay off 40 percent of workforce as it restructures
01/06/2025
4
All You Need to Know About CytomX Therapeutics Rating Upgrade to Strong Buy
01/07/2025
5
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
01/08/2025
6
SANA Stock Surges 152 percent in a Week on Upbeat Initial Diabetes Study Data
01/10/2025
7
ITCI Stock Rises 15 percent on Settling Caplyta Patent Litigation With Sandoz
01/13/2025
8
CytomX Therapeutics, Inc. Given Average Recommendation of Moderate Buy by Analysts
01/14/2025
9
MIRM Shares Rise 12 percent in a Week on Robust Preliminary 2024 Results
01/16/2025
10
Shareholders in CytomX Therapeutics are in the red if they invested five years ago
01/29/2025
11
Analysts Set CytomX Therapeutics, Inc. Target Price at 5.77 - MarketBeat
02/11/2025

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…